| abstract |
The invention relates to polypeptides and single variable domains (dAb) of an anti-IL-1R1 antibody that are resistant to protease degradation, as well as antagonists containing them. These polypeptides, dAb and antagonists are useful as therapeutic and / or prophylactic agents that are likely to encounter proteases when administered to a patient, for example for intrapulmonary administration, oral administration, delivery to the lung and delivery to the patient’s gastrointestinal tract, gastrointestinal tract, and for the treatment of an inflammatory disease such as arthritis or COPD (chronic obstructive pulmonary disease). |